Why Drug Release and Mucosal Permeation Are Different Measurements

Drug release and mucosal permeation are different measurements because release asks how much peptide leaves the oromucosal film, while permeation asks how much of the released peptide crosses a biological mucosal barrier. A formulation can release peptide rapidly but show poor mucosal transport, or release more slowly while maintaining a concentration gradient against the tissue for longer. The two measurements therefore need separate experiments and should not be treated as interchangeable evidence of absorption or bioavailability.

This distinction is foundational in oromucosal peptide film research because film performance is a sequence rather than one event:

film hydration → peptide release → mucosal contact → tissue permeation → vascular uptake → systemic exposure.

Research-use notice for comparing peptide release with mucosal permeation: InStrips products are offered for laboratory research and analytical use only. Experimental findings about peptide release from oromucosal films, mucosal transport, diffusion, or barrier permeation are not intended to diagnose, treat, cure, or prevent any disease, injury, peptide deficiency, absorption disorder, digestive condition, or other medical condition.

Release Happens Before the Biological Barrier

Imagine a peptide molecule embedded within a polymeric film.

Before it can cross mucosa, it generally must first:

• become hydrated
• dissolve or become mobile
• diffuse out of the matrix

That sequence is what release testing examines.

Permeation Begins After the Peptide Reaches the Tissue Interface

Once the peptide is available at the mucosal surface, it still has to cross:

• mucus
• epithelium
• intercellular barriers
• potential enzymatic environments

before reaching the opposite side.

A Release Curve Does Not Contain a Biological Barrier

A typical dissolution experiment may involve:

• film
• aqueous medium
• agitation

There is no living or excised mucosal epithelium between the film and the sampling medium.

A Permeation Experiment Adds That Missing Barrier

A typical ex vivo setup contains:

film → mucosal tissue → receptor medium.

The tissue can drastically alter the amount and rate of peptide reaching the receptor side.

This Difference Can Be Demonstrated Experimentally

Buccal-film studies have reported formulations with very similar dissolution behavior but substantially different permeation through a membrane or biological barrier.

This shows that release rate alone cannot predict transport reliably.

Why Two Films Can Release Similarly but Permeate Differently

The peptide may differ in:

• charge state
• molecular size
• lipophilicity
• interaction with mucosal tissue
• enzyme susceptibility

even when release from the matrix is similar.

The Film Can Also Alter Mucosal Transport Independently of Release

Formulation components may influence:

• local pH
• mucosal hydration
• junctional permeability
• peptide partitioning

This can change permeation without dramatically changing dissolution.

Permeation Enhancers Illustrate the Difference Clearly

Suppose two films release 80% of their peptide within the same period.

If one contains a functional permeation enhancer, it may produce:

• greater mucosal flux
• greater cumulative transport

despite nearly identical release curves.

Mucoadhesion Can Produce the Opposite Pattern

A strongly mucoadhesive film may release peptide gradually but keep it concentrated against the mucosal surface.

This can maintain a local gradient for longer.

Fast Release Can Sometimes Increase Loss Into Saliva

In vivo, peptide released away from the mucosal interface may be:

• diluted by saliva
• swallowed
• degraded

before it permeates tissue.

Therefore Faster Release Is Not Automatically Better Delivery

The useful release rate depends on:

• mucosal permeability
• residence time
• saliva exposure
• peptide stability

Release Can Be Rate Limiting

If a peptide crosses mucosa relatively readily but leaves the film very slowly, film release may control the overall delivery rate.

Permeation Can Also Be Rate Limiting

If the film releases the peptide almost immediately but the mucosa is highly restrictive, the biological barrier becomes the dominant limitation.

The Slowest Step Can Control the Overall Process

Conceptually:

overall delivery rate ≈ rate imposed by the dominant barrier.

That barrier may be:

• film matrix
• mucosa
• enzymatic degradation
• another downstream process

Peptides Often Make Mucosal Permeation the More Difficult Step

Many peptides are:

• hydrophilic
• charged
• larger than typical small-molecule drugs

which can limit passive transcellular transport.

Paracellular Transport Is Also Restricted

The spaces between epithelial cells are controlled by junctional structures.

These pathways do not freely admit every peptide that reaches the mucosal surface.

Release Tests Usually Use Non-Biological Media

The peptide may be released into:

• phosphate buffer
• simulated saliva
• other dissolution medium

without encountering a physiological barrier.

Permeation Tests Use a Barrier With Its Own Chemistry

Mucosa introduces:

• lipids
• proteins
• enzymes
• cell membranes
• tight junctions

that can change peptide behavior.

Peptide Degradation Can Occur Between Release and Permeation

A film may successfully release intact peptide, but the peptide can then be degraded by:

• salivary enzymes
• mucosal peptidases

before crossing the tissue.

This Creates a Third Measurement: Chemical Stability

A complete film study may therefore need to distinguish:

• how much peptide was released
• how much remained intact
• how much crossed the tissue

These Three Percentages Need Not Match

For example, a formulation might show:

• 90% total release
• 70% intact peptide remaining in the donor environment
• 10% crossing the mucosa

Those hypothetical numbers would describe three different stages.

Cumulative Release Is Usually Expressed Relative to Film Loading

Researchers may report:

percentage of loaded peptide released.

Cumulative Permeation Can Be Expressed Relative to Area

Permeation is often reported as:

• µg/cm²
• percentage transported
• flux

The units themselves show that the measurements answer different questions.

Flux Has No Direct Equivalent in a Simple Dissolution Test

Flux describes movement across an area of biological barrier per unit time.

A release test without mucosa does not contain that barrier.

Release Kinetic Models and Permeation Models Can Also Differ

Researchers may analyze release using models related to:

• matrix diffusion
• erosion
• polymer relaxation

while permeation may be interpreted through:

• Fickian diffusion
• flux
• apparent permeability

A Similar Mathematical Shape Does Not Make the Processes Identical

Both curves may appear approximately linear or first order over part of the experiment.

The underlying barriers remain different.

Film Thickness Can Strongly Affect Release

A thicker matrix can increase diffusion distance within the formulation.

It may have less direct influence on intrinsic mucosal permeability once the peptide reaches the tissue surface.

Permeation Enhancers Can Affect the Tissue More Than the Film

A formulation component might have only a small effect on release but a large effect on:

• epithelial permeability
• junctional structure

This is another reason the two endpoints should be measured separately.

Backing Layers Can Separate Release Direction From Total Release

A bilayer or multilayer film may be designed so that peptide release occurs primarily toward:

• the mucosa

rather than toward:

• the oral cavity

Standard Dissolution Testing Can Miss This Directionality

If the whole film is submerged, researchers may measure total release without reproducing the intended one-sided delivery.

Directional Permeation Testing Can Better Reflect the Design

Placing the mucoadhesive surface against tissue and the backing layer away from it can preserve the intended orientation.

A Fast-Dissolving Film Is Not Necessarily a Transmucosal Film

Some oral films are designed mainly to:

• dissolve in saliva
• be swallowed

while buccal or sublingual films may be designed to promote mucosal uptake.

Classification Matters

An orodispersible film and a mucoadhesive transmucosal film can use similar materials while serving different delivery objectives.

The Intended Route Determines Which Measurement Matters Most

For a film intended primarily for gastrointestinal delivery after swallowing, dissolution may be especially important.

For a film intended for transmucosal peptide delivery, release and mucosal permeation both become critical.

Ex Vivo Permeation Still Does Not Equal In Vivo Absorption

Even after a peptide crosses excised mucosa in a Franz cell, a living organism adds:

• blood flow
• vascular uptake
• systemic metabolism
• clearance

before systemic exposure can be characterized.

This Creates a Longer Evidence Chain

film release → ex vivo permeation → in vivo absorption → plasma concentration-time profile.

Each arrow represents a different experimental problem.

In Vitro-In Vivo Correlation Is Therefore Challenging

A 2026 buccal-film review specifically highlights limitations in establishing predictive relationships among:

• in vitro release
• ex vivo permeation
• in vivo pharmacokinetics

because formulation factors can influence each stage differently.

One Good Release Result Cannot Substitute for the Missing Stages

If a film releases 100% of its peptide in 15 minutes, researchers still do not know:

• how much remains intact at the mucosa
• how much permeates
• how much reaches blood
• what plasma exposure results

One Good Permeation Result Cannot Substitute for Human PK Either

An ex vivo flux value remains a laboratory tissue measurement.

It does not define:

• Cmax
• Tmax
• AUC

in humans.

Research Note: Release Tells You Whether the Peptide Escaped the Film

Permeation tells you whether it crossed the mucosal barrier. Those two questions sound similar because both produce concentration-versus-time curves, but they represent different physical stages of delivery.

A scientifically complete oromucosal film evaluation therefore avoids using phrases such as “better absorption” when the experiment measured only dissolution or release.

Release Methods Come First in the Sequence

How researchers characterize the film-to-medium stage is described in how peptide release from oromucosal films is measured.

What Release Data Can Establish

Release experiments can provide evidence about:

• matrix performance
• release rate
• fraction released
• formulation effects

What Permeation Data Can Establish

Ex vivo experiments can provide evidence about:

• transport through mucosa
• flux
• lag time
• effects of permeation enhancers

What Neither Measurement Establishes Alone

Neither release nor ex vivo permeation independently establishes:

• human systemic exposure
• relative bioavailability
• clinical effectiveness
• an appropriate human dose
• long-term safety

Questions to Ask When a Film Study Claims Better Delivery

• Was release measured or permeation measured?
• Was a biological mucosal barrier present?
• Was intact peptide quantified?
• Was tissue integrity checked?
• Was the result percentage released, percentage permeated, or flux?
• Was there an in vivo PK study?
• Was systemic exposure measured directly?

A 2026 review connecting buccal-film formulation design with pharmacokinetic control explicitly treats release, mucosal permeation, and in vivo pharmacokinetics as related but separate stages whose correlations remain an important translational challenge.

Final Perspective

Drug release and mucosal permeation should be treated as sequential but independent measurements.

Release asks whether the peptide becomes available from the film. Permeation asks whether that available peptide crosses the mucosal barrier. A formulation can perform well at one stage and poorly at the other because the governing barriers are different.

This distinction becomes especially important for peptides, where mucosal permeability and enzymatic stability can remain limiting even when the film releases the peptide rapidly and completely. Systemic exposure therefore requires another measurement layer beyond both release and ex vivo permeation.